Michael C. Swartzburg serves as Interim Principal Financial Officer and Principal Accounting Officer of the Company. He has served as the Company’s Vice President, Finance since March 2018. Previously, Mr. Swartzburg provided contracted financial and board of director advisory services to various public and private biotechnology and technology companies from August 2016 through March 2018. From June 2014 to August 2016, Mr. Swartzburg served in roles at Adverum Biotechnolgies, Inc., formally known as Avalanche Biotechnologies, Inc., including serving as Vice President, Finance, Controller, and Principal Accounting Officer. Prior to joining Adverum, Mr. Swartzburg served as Vice President, Finance and Corporate Controller for One Medical Group, a healthcare provider and technology company from June 2013 through June 2014. From August 2009 to June 2013, Mr. Swartzburg served as the Corporate Controller for MAP Pharmaceuticals, Inc., a publicly held biopharmaceutical company, which was acquired by Allergan, Inc. in February 2013. Mr. Swartzburg started his career as a certified public accountant and auditor at Ernst & Young, LLP, in Los Angeles, California. Mr. Swartzburg received his B.S. in Business Administration, with an option in Accounting, at California State University, Northridge.
Michael Swartzburg is 53, he's been the Interim Principal Financial Officer and Principal Accounting Officer of Iovance Biotherapeutics Inc since 2020. There are 6 older and 8 younger executives at Iovance Biotherapeutics Inc. The oldest executive at Iovance Biotherapeutics Inc is Merrill McPeak, 84, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O IOVANCE BIOTHERAPEUTICS, INC., 999 SKYWAY ROAD, SUITE 150, SAN CARLOS, CA, 94070.
Over the last 8 years, insiders at Iovance Biotherapeutics Inc have traded over $0 worth of Iovance Biotherapeutics Inc stock and bought 22,614,553 units worth $159,655,586 . The most active insiders traders include Wayne P. Rothbaum, Merrill A Mcpeak, eTimothy E Morris. On average, Iovance Biotherapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $3,815,146. The most recent stock trade was executed by Frederick G Vogt on 3 September 2024, trading 57,292 units of IOVA stock currently worth $535,680.
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
Iovance Biotherapeutics Inc executives and other stock owners filed with the SEC include: